enGene Holdings Inc., a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced today that it has entered into an amended $67 million (US$50 million) loan agreement with Hercules Capital, Inc.

Under the loan agreement, which has a term of four years, $22.5 million has been advanced to enGene under a non-revolving term loan and, subject to certain clinical and financial milestones, up to a further $27.5 million in loan proceeds may be available subject to the satisfaction of certain terms and conditions.

Under the terms of the agreement, the principal amount outstanding and all accrued but unpaid interest under the Term Loan Facility shall be repaid on or before January 1, 2028 (or such later dates as to which the maturity date may be extended from time to time following the terms of the loan agreement).